Methods of treating copd

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 45/06 (2006.01) A61K 31/00 (2006.01) A61K 31/341 (2006.01) A61K 31/366 (2006.01) A61P 11/00 (2006.01) A61P 29/00 (2006.01) A61P 43/00 (2006.01)

Patent

CA 2706883

Disclosed is a method of treating chronic obstructive disease, said method comprising administering an effective amount of a CXCR2 antagonist and administering an effective amount of at least one drug selected from the group consisting of: angiotensin-converting enzyme inhibitors, Angiotensin II receptor antagonists, cardioselective beta blockers, and lipid regulating drugs. Examples of the CXCR2 antagonist include: (formula 1.0A and 1.0B).

La présente invention concerne un procédé permettant de traiter une broncho-pneumopathie chronique obstructive, ledit procédé comprenant l'administration d'une quantité efficace d'un antagoniste de CXCR2 et l'administration d'une quantité efficace d'au moins un médicament choisi dans le groupe constitué par les inhibiteurs de l'enzyme de conversion de l'angiotensine, les antagonistes des récepteurs de l'angiotensine II, les bêtabloquants cardiosélectifs, et les médicaments lipo-régulateurs. Des exemples d'antagoniste de CXCR2 comprennent : (formule 1.0A et 1.0B).

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Methods of treating copd does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treating copd, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating copd will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1341572

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.